OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

European Innovation Council is a European Union initiative established in 2018 to support deep-technology innovation and help startups, researchers, and small companies scale. It offers funding opportunities and business acceleration services, and engages in co-investment with private investors in early-stage ventures with ESG impact. The EIC emphasizes female entrepreneurship through programs such as Women TechEU and related awards, and provides resources to promote knowledge sharing and community building. Based in Brussels, it pursues a European-wide mandate to strengthen Europe's position in the global deep-tech ecosystem.

General Catalyst is a venture capital firm that funds early-stage and growth companies across sectors including consumer, enterprise software, fintech, crypto, and healthcare. Based in San Francisco with offices in Cambridge, Massachusetts and other locations, it provides capital and strategic guidance to help entrepreneurs build scalable, durable businesses. The firm emphasizes the use of technology, including artificial intelligence, to accelerate growth and drive meaningful impact. General Catalyst partners with management teams to support product development, go-to-market strategies, and organizational growth, aiming to back companies with potential for wide adoption and long-term value creation, rather than focusing solely on near-term exits.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo. It enables accredited investors, especially alumni networks, to access diversified venture opportunities by co-investing alongside leading venture capital firms. Through funds, syndicates, and investing clubs, it sources opportunities across stages and geographies, conducts rigorous due diligence, and aims for transparent, founder-friendly support. The firm backs a diversified portfolio of startups, including more than 1,600 companies, and has attracted substantial committed capital and a large community of individual investors, underscoring its mission to democratize access to venture capital while partnering with established VC firms.

Deerfield Management is a New York City-based healthcare investment and information platform that advances healthcare through flexible funding models, AI-driven intelligence, and philanthropy. It connects people, capital, ideas, and technology across the healthcare ecosystem by investing in and building companies, powered by Deerfield Discovery and Development (3DC), a company-building R&D engine where bench scientists and industry veterans collaborate, and Cure, a New York City hub housing portfolio companies and in-building labs with advanced equipment. It has partnered with Blue Cross Blue Shield of North Carolina to build Alo, a platform enabling independent physicians to manage the business of medicine. Its Intelligence offering leverages AI, data, and market research to drive healthcare technology and innovation, while the Deerfield Foundation funds philanthropic initiatives in education, healthcare access, and health outcomes. The firm pursues strategic partnerships and external collaborations to accelerate progress across biotechnology, pharmaceuticals, diagnostics, devices, and services.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Samsara BioCapital is a Palo Alto-based venture capital firm focused on biotechnology and transformative therapeutics. Founded in 2016, it invests in the healthcare sector across the United States and operates as an investment adviser. The firm collaborates with scientists, physicians, drug developers, and business leaders to support ambitious biotechnology companies and advance a portfolio of therapeutic projects aimed at delivering innovative medicines to patients.

Andreessen Horowitz is a Menlo Park, California-based venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It funds technology startups across seed to late stages, with investments spanning software, cloud infrastructure, enterprise software and services, consumer internet, fintech, artificial intelligence, crypto, infrastructure, and biotechnology at the intersection of computer science and life sciences. The firm emphasizes supporting portfolio companies through growth and strategic partnerships and maintains a broad tech-focused investment approach, aiming to add value beyond capital.

Mission BioCapital is a life science venture capital firm focused on early-stage investments in biotechnology and related life sciences in the United States, with offices in Cambridge, Massachusetts and San Francisco. The leadership team has a long history of launching dozens of early-stage life science companies and a track record of providing deep expertise and support to portfolio companies. The firm emphasizes mentorship, collaboration, and founder-centric value creation, and offers programs such as the Platinum Program, which provides up to $500,000 in funding along with lab space and services including drug discovery, legal and financial assistance to accelerate development.

Legend Capital is a Beijing-based venture capital firm founded in 2001 and affiliated with Legend Holdings. It focuses on early-stage venture capital and growth equity investments in China and markets related to China, aiming to back high-growth technology-enabled companies and cross-sector ventures. The firm concentrates on sectors such as information technology, communications, consumer, healthcare, industrials, and modern services, with an emphasis on companies that leverage China's scale and ecosystem. Legend Capital provides portfolio companies with strategic resources, network access, and operational support to accelerate business development in the Chinese market and beyond. Over the years, it has built a substantial portfolio of companies and exited a number of investments through various channels, reflecting its role in supporting entrepreneurship and ecosystem development in China's venture capital landscape. The firm operates from offices in major Chinese cities and Hong Kong to support entrepreneurs and partners across the region.

Gaingels is a venture investment syndicate focused on supporting LGBTQ founders and inclusive leadership by investing across stages and partnering with other venture firms to back diverse, high-potential companies. It maintains a global portfolio of 130+ companies and has deployed tens of millions in capital to date. The organization actively helps portfolio companies identify and recruit diverse talent for C-suite and board roles and cultivates a worldwide network of investors, operators, and entrepreneurs who share a commitment to positive social change through business.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a nonprofit organization founded in 1982 that supports the technology ecosystem in Southeastern Pennsylvania by providing capital, guidance, and connections to early-stage technology companies. It acts as a seed-stage capital provider for the region's technology sectors, facilitates university-industry partnerships to accelerate commercialization, and undertakes initiatives to strengthen the entrepreneurial community across Philadelphia and surrounding counties, with a focus on creating jobs and fostering regional innovation.

Forbion is a venture capital firm based in Naarden, Netherlands, with over twenty years of experience investing in biotech and life sciences. It focuses on human health, planetary health, and the bioeconomy, supporting early-stage and growth investments across Europe and North America in drug development, MedTech, and sustainable solutions. Its portfolio includes gene therapy and other innovative therapies for rare diseases. Forbion manages funds totaling about €5 billion in committed capital across multiple vehicles and prioritizes ESG principles in its investment approach, seeking to accelerate scientific advances and drive long-term value for portfolio companies.

8VC is a San Francisco-based technology and life sciences investment firm that partners with founders to develop transformational technologies and create long-term economic and societal value. It invests across sectors including healthcare and life sciences, energy, IT infrastructure, enterprise software, logistics, government and defense, manufacturing, consumer products, and financial services, with a focus on opportunities that leverage data-driven decision making. The firm supports portfolio companies through programs such as the 8VC Fellowship and 8VC Build and aims to back ventures where existing solutions do not meet market needs. 8VC manages a family of venture funds, including Entrepreneurs Fund II and III and multiple Fund I–III vehicles, reflecting a broad platform designed to accelerate growth and industry transformation.

Sofinnova Partners is an independent venture capital firm based in Paris, France, specializing in life sciences investments from seed to later stages. It backs start-ups, early-stage companies, corporate spin-offs, and occasionally turnarounds, with a focus on biopharmaceuticals, biotechnology, medical devices, industrial biotechnology and related healthcare sectors. The firm typically takes a lead or cornerstone investor role, often chairs or sits on boards, and supports portfolio companies from formation through growth toward exit. Founded in 1972, it has a long track record in partnering with entrepreneurs and managing substantial assets dedicated to life sciences investing.

Mitsubishi UFJ Capital is a Tokyo-based venture capital firm established in 1974 that funds seed, development-stage and startup companies in Japan, focusing on life sciences, healthcare, biotechnology, information technology, electronics and other high-technology sectors such as fintech and AI. It pursues cross-border opportunities and investment syndication, often collaborating with MUFG and international partners to support portfolio companies’ growth and access to overseas markets, and to connect Japanese portfolio companies with strategic partners and potential exits.

SR One is the corporate venture capital arm of GlaxoSmithKline, a trans-Atlantic biotechnology investor focused on funding innovative science to develop new medicines. It operates from biotechnology hubs on the West Coast and in London, leveraging its cross-Atlantic presence to provide strategic partnerships, geographic reach, and portfolio support that accelerates the translation of scientific breakthroughs into medicines. Founded in 1985, SR One has invested about 800 million dollars in more than 180 life science companies, and it employs a back-and-build approach that prioritizes strong scientific fundamentals, clear development plans, and novel approaches to disease treatment.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across Europe. It manages multiple funds, including early-stage life sciences funds, to support therapeutic and medical innovations from early concept to development, with active collaboration with academic research institutes and hospitals. The firm emphasizes a collaborative, hands-on approach, providing capital and strategic guidance to portfolio companies, often forming strong partnerships with research teams to translate scientific discoveries into medicines and medical devices. Kurma Partners targets investments in life sciences, pharmaceuticals, biotechnology, digital health and related technology sectors, and pursues opportunities across Europe, integrating ESG practices into its investment processes.

Right Side Capital Management is a San Francisco-based venture capital firm founded in 2012 that targets early-stage, capital-efficient technology startups in the United States and Canada. The firm employs a data-driven, quantitative approach to investment decisions and aims for rapid yes-or-no conclusions, often within two weeks. Typical rounds encompass small checks in the low hundreds of thousands, with the potential for larger commitments in exceptional cases, and a portfolio-wide strategy that emphasizes diversification. Beyond capital, it provides hands-on mentorship in areas such as sales, marketing, and fundraising, leveraging a network of investors and seasoned operators to support portfolio companies after investment. The firm focuses on teams still refining product-market fit, including those outside traditional tech hubs, and seeks to help founders scale efficiently through structured operational support and transparent decision processes.

IMM Investment is a Seoul-based asset manager and private equity firm specializing in venture capital, growth equity, infrastructure, mezzanine and multi-asset strategies. Founded in 1999, it operates across Asia with offices in Seoul, Tokyo and Hong Kong, and pursues investments in information technology, healthcare/biotech and manufacturing, as well as technology-enabled sectors such as IT infrastructure and digital hardware. The firm emphasizes active ownership, collaboration with portfolio companies, and cross-border opportunities, including fund-of-funds and real estate. It targets mid-sized companies in South Korea and broader Asia, focusing on value creation through growth, mergers and acquisitions, and strategic recapitalizations, and manages a multi-stage investment approach across startups, expansion and mezzanine rounds. The team, comprising seasoned investment professionals, aims to deliver strong risk-adjusted returns and supports entrepreneurs through various growth phases.

Takeda Pharmaceutical is a global biopharmaceutical leader and Japan’s largest pharmaceutical company. It researches, develops, manufactures, and markets prescription medicines and vaccines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company serves patients worldwide with a diversified geographic footprint—roughly half of revenue from the United States, about 10% from Japan, 25% from Europe, and 15% from Canada. Takeda emphasizes patient-centered growth, sustainability, and ethical practices, supported by a strong focus on research and development to translate science into transformative medicines.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

HBM Healthcare Investments is a Swiss investment company that concentrates on the global healthcare sector, seeking to capitalize on innovation across private and public healthcare companies. Founded in 2001 and based in Switzerland, it maintains a diversified portfolio spanning human medicine, biotechnology, medical technology and diagnostics, with investments across private companies, public equities, and funds. The firm emphasizes high-value creation potential through its portfolio and positions itself to benefit from demographic trends, medical advancements and rising demand for new therapies.

Sequoia Capital is a venture capital firm founded in 1972 and based in Menlo Park, California. It provides capital and strategic guidance to seed, early, and growth-stage technology companies, focusing on software, information technology, internet, and related sectors. The firm operates globally, with investments and activity across the United States, China, India, Israel, and other markets through a network of regional partners. Sequoia Capital emphasizes selective, long-term partnerships, working closely with portfolio companies to assist with product development, business building, and market expansion to support durable growth.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

IDG Capital is a global investment firm with over 30 years of experience, originating in China and headquartered in Hong Kong. It finances companies across venture capital, growth equity, buyouts, secondary markets and public markets, supporting a lifecycle from early stage to scale. The firm maintains a worldwide presence with offices across the Americas, Europe and Asia Pacific, and backs a large portfolio through long-term, value-driven partnerships with founders. IDG Capital leverages a combination of local market insight and global resources to identify inbound and outbound opportunities in China and other Asian markets, while collaborating with sovereign wealth funds, pension funds, and other institutional investors as limited partners. Its track record includes hundreds of exits and involvement in notable growth stories across technology, consumer, healthcare and other sectors, reflecting a disciplined approach to building lasting companies.

Shenzhen Capital Group is a government-backed venture capital firm founded in 1999 and based in Shenzhen, China. It concentrates on SMEs and innovative high-tech enterprises in emerging industries, including IT, internet, new media, biopharma, new energy, environmental protection, new materials, chemical engineering, and high-end equipment manufacturing, supporting companies in the start-up, growth and transformation stages. The group pursues a long-term, ESG-conscious investment approach and leverages a dense funding network to connect government, industry and academia, promoting regional innovation from the Guangdong-Hong Kong-Macao Greater Bay Area to inland corridors. Its portfolio spans leading Chinese technology and manufacturing firms, reflecting a broad footprint across semiconductors, healthcare, energy and industrial tech, with assets under management of about 339 billion RMB.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

CDH Investments is a China-based international private equity and diversified alternative asset manager founded in 2002. It operates a multi-asset platform spanning private equity, venture, growth capital, real assets, credit and mezzanine, public equities and wealth management, with a focus on investments in Greater China and Southeast Asia. The firm targets opportunities across consumer, technology, energy and healthcare sectors and seeks long-term value creation through partnerships with leading enterprises and institutional investors. Its experienced team collaborates across platforms to support growth, transformations and strategic exits, positioning CDH Investments as one of China’s early professional alternative asset managers with a broad track record of cross-border and domestic investments.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

Boxer Capital is the corporate venture capital arm of Tavistock Group that concentrates its investments in biotechnology and life sciences. Based in San Diego, California, the firm pursues opportunities in both private and public biotechnology companies across the entire drug development lifecycle, from early discovery assets to late-stage clinical and commercial programs. It combines scientific expertise with investment experience to evaluate targets across therapeutic areas, emphasizes precision medicine, and seeks to support transformative medical advances through disciplined, research-driven analysis and active partnerships with portfolio companies.

Merck is a global pharmaceutical company focused on discovering, developing, and delivering medicines and vaccines to treat cancer, infectious diseases, and other conditions. It emphasizes oncology through its immuno-oncology platform, with Keytruda as a major product contributor, and maintains a substantial vaccine business that includes Gardasil to prevent human papillomavirus infections. The company also targets cardiometabolic, infectious, immunology, neuroscience, and ophthalmology areas, supported by a robust pipeline and clinical development efforts powered by data science and AI. Merck pursues responsible operations, sustainability initiatives, and patient access programs, while maintaining transparency with stakeholders. Its activities span global markets, with emphasis on innovative partnerships to expand healthcare impact and address unmet medical needs.

StartUp Health is a global health innovation organization founded in 2011 that supports entrepreneurs and health innovators to improve health and wellbeing. It partners with a broad ecosystem of founders, funders, and healthcare leaders to pursue health moonshots such as access to care, cure disease, end cancer, women’s and children’s health, mental health, and pandemic response. It operates the world’s largest portfolio of health technology companies, with more than 330 companies across six continents and 26 countries, and is backed by major health systems and investors including Kaiser Permanente, Masimo, Novartis, Otsuka, Ping An, Steve Case, Mark Cuban, and Esther Dyson. The organization focuses on collaboration, knowledge sharing, and ecosystem programs that connect startups, scaleups, established companies, and providers, and it hosts events to accelerate progress in priority health areas.

Sherpa Healthcare Partners is a Beijing-based venture capital firm founded in 2018 that concentrates on life sciences and healthcare investments, including pharmaceuticals, biotechnology, gene technologies, medical devices, diagnostics, and healthcare services. It focuses on cultivating sector leaders and innovators by providing strategic guidance, operational support, and industry relationships to portfolio companies within China's healthcare ecosystem.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Northern Light Venture Capital is a venture capital firm founded in 2005 that backs early- and growth-stage technology-driven companies. It targets opportunities in information technology, healthcare, consumer sectors, and related industries, with a China-focused approach that aims to leverage China’s industrial, economic, and human resources to build enduring global enterprises. The firm manages multiple funds to support its portfolio, including RMB funds and US-dollar vehicles.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab. It focuses on seed- and early-stage investments in life sciences and healthcare, including biopharmaceuticals, biotechnology, drug delivery, medical technology, and research instruments, with additional interest in digital health and health technology. The firm maintains a Boston office and targets opportunities across the United States and North America, partnering with academics and entrepreneurs to build next-generation life science companies. It also operates an internal initiative called 4:59 to identify, incubate, and fund breakthrough science.

Founded in 2013, Gaorong Capital is a Beijing-based venture capital firm that targets early-stage technology investments in the Asia-Pacific region. The firm backs companies across telecommunications, media, life sciences, cosmetics, and technology, helping them scale through strategic resources and guidance. Its investor base includes sovereign wealth funds, university endowments, pension funds, foundations, and funds of funds, as well as entrepreneurs from leading technology groups who contribute industry experience and global perspectives.

Med-Fine Capital is a Shanghai-based venture capital firm founded in 2014 that focuses on early-stage investments in China's healthcare and life sciences sectors, with offices in Beijing and Shenzhen.

SMBC Venture Capital is the venture capital arm of Sumitomo Mitsui Banking Corporation, focusing on growth equity and buyouts across information technology, life sciences, services, and manufacturing. Founded in 2005 and headquartered in Tokyo with an office in Osaka, it leverages the SMBC network to connect portfolio companies with large corporates, talent, and specialists, providing stage-appropriate, coordinated support through its integrated team. The firm pursues a long-term, growth-focused approach and invests across industries and stages, aiming to back companies that improve lives and address social challenges. Its portfolio has included more than 400 companies that have achieved initial public offerings, reflecting its emphasis on value creation alongside entrepreneurs.

Lux Capital is a venture capital firm focused on investing in companies at the intersection of science, technology, and industry. The firm backs ventures applying research across sectors including artificial intelligence, biotechnology, advanced materials, space, and energy, with an emphasis on translating complex innovations into scalable businesses. Lux provides capital together with strategic input on product development, company building, and long-term positioning, and takes an active role to help founders navigate technical and market challenges. The firm evaluates opportunities based on the underlying science, potential industry impact, and feasibility of execution over extended horizons. With offices in New York and Silicon Valley, Lux collaborates with technical founders, researchers, and teams to build durable market leaders and accelerate scientific breakthroughs into real-world applications.